Adlai Nortye Valuation

Q: What is the Fair Price of N2U0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

N2U0 (€10.9) is trading below our estimate of [[fair value]] (€934.1)

Is N2U0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of N2U0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: N2U0 (€10.9) is trading below our estimate of fair value (€934.1)

Significantly Below Fair Value: N2U0 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for N2U0?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for N2U0. This is calculated by dividing N2U0's market cap by their current preferred multiple.
What is N2U0's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	US$107.38m

N2U0 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	9.8x
Enterprise Value/EBITDA	-0.8x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does N2U0's PS Ratio compare to its peers?

The above table shows the PS ratio for N2U0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	9.8x
HPHA Heidelberg Pharma	11.8x	12.3%	€112.3m
2INV 2invest	7.8x	n/a	€60.4m
MDG1 Medigene	4.2x	16.1%	€31.6m
FYB Formycon	15.4x	31.8%	€937.6m
N2U0 Adlai Nortye	21.5x	71.7%	€107.4m

Price-To-Sales vs Peers: N2U0 is expensive based on its Price-To-Sales Ratio (21.5x) compared to the peer average (9.4x).

Price to Earnings Ratio vs Industry

How does N2U0's PE Ratio compare vs other companies in the DE Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	35.4%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	35.4%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: N2U0 is expensive based on its Price-To-Sales Ratio (21.5x) compared to the European Biotechs industry average (10.5x).

Price to Sales Ratio vs Fair Ratio

What is N2U0's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

N2U0 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	21.5x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate N2U0's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.